openPR Logo
Press release

High Potency Active Pharmaceutical Ingredient Market Set to Record exponential growth by 2023 End

10-02-2017 09:52 AM CET | Health & Medicine

Press release from: TMR - Research Reports

High Potency Active Pharmaceutical Ingredient Market Set

Transparency Market Research has estimated that the HPAPI market valued at US$2.64 bn in 2014 and expected to reach US$25.11 bn by 2023, while exhibiting a steady CAGR 8.3% during the forecast period 2015-2023.

Extensive Research and Development Aimed at Cost-efficiency to accelerate the Market Growth

The high potency active pharmaceutical ingredient market is expected to grow exponentially over the next few years due to rising cases of diabetes, cancer, and various cardiovascular diseases and the booming ongoing oncology research. The cost of drugs have been reduced due the cost containment strategies followed by the players in this market. This has in turn made these drugs more affordable to a larger audience. This trend has boosted the market and is expected to help the market grow in the coming years. Furthermore, promising pipeline of targeted therapeutic drugs is most likely to add advantage to the market growth. Without any lingering after effects, these drugs help patients to impact targeted areas and recover faster. Continuous development and research going on in mimic branded drugs are envisioned to create cost-effective treatments, further accelerating the growth of the market.

View and Download TOC of High Potency Active Pharmaceutical Ingredient (HPAPI) Market Research Report@ https://www.transparencymarketresearch.com/report-toc/748

Post treatment effects of chemotherapy such as infection to non-cancerous cells are motivating numerous health facilities to adopt targeted therapy as they do not harm non-cancerous cells. This trend is expected to fuel the market growth during the forecast period. HPAPI are extensively used in hormonal drugs that are used for treatment of breast cancer. The other prominent applications of HPAPI is for the treatment of glaucoma. The increasing incidences of glaucoma is most likely to poise to the growth of the market. Applications of HPAPIs in musculoskeletal drugs, central nervous system drugs, and cardiovascular drugs are increasing adding benefits to growth of the market.

High Labor Cost for Drug Manufacturing Could Impede Market Growth

The capital intensive nature of manufacturing activities of high potency active pharmaceutical ingredient have been a major subject of concern for the players in this market. Furthermore, the manufacturing of these drugs need highly skilled labors, which could increase the labor cost hence the cost of the pharmaceutical ingredient. This can act as a restraining factor for growth of the market. In addition, the absence of norms pertaining to environmental, health, and occupational safety while manufacturing and researching potency APIs is threatening the market growth.

Nevertheless, the increasing incidence of cancer are expected to help the market sustain its growth. The escalating occurrence of cancer have augmented the research and development activities in healthcare sectors of various regions such Asia Pacific and North America. This has resulted in the increased demand for effective anticancer drugs, assisting growth of the high potency active pharmaceutical ingredient market.

Request and Download Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=748

Regionally, Asia Pacific is expected to show significant opportunities to the market due to soaring contract manufacturing activities in the region. Within this region, Japan contributes the leading share. However, due to supportive foreign exchange policies, well-equipped manufacturing plants, and low labor costs, China is expected to surpass Japan’s total revenue in the forthcoming years.

The vendor landscape of the global high potency active pharmaceutical ingredient (HPAPI) market is highly fragmented due to presence of a large number of players. Some of the prominent players in this market are WuXi AppTec, Pfizer, Inc., Novartis AG, Lonza Group, Novasep, Dr. Reddy’s Laboratories Ltd., Cambrex Corporation, and Sigma-Aldrich Corporation. Transparency Market Research has estimated that the individual revenue share of these players range between 3% and 4% of the overall market. These players are focusing on cost containment to sustain their profit margins. Furthermore, various companies in this market are involving in strategic partnerships to remain significant occupant and gain the first-mover advantage in the market.

Buy Full High Potency Active Pharmaceutical Ingredient (HPAPI) Market Report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=748<ype=S

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release High Potency Active Pharmaceutical Ingredient Market Set to Record exponential growth by 2023 End here

News-ID: 749923 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for HPAPI

HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures. Key highlights include: Alternative HPAPI manufacturing technologies to
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements. Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other
HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca
Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing. Peter said: “The
The Latest Techniques in HPAPI Facility Design
Amongst the myriad of potential pitfalls for the Highly Potential Active Pharmaceutical Ingredients (HPAPI) industry there is a requirement for all parties involved to have a blueprint in place to ensure all containment procedures are followed correctly. Yet, there is also a need to ensure that operations are maintained at the highest standards. At SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients Conference these issues will be discussed along with
HPAPI (High Potency Active Pharmaceutical Ingredients) Market Report 2018: Segme …
Global HPAPI (High Potency Active Pharmaceutical Ingredients) market research report provides company profile for Lonza, Novasep, Thermofisher Scientific, Alkermes, Cambrex, Dishman, Dr. Reddy’S and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report